Administration of recombinant granulocyte colony-stimulating factor to neonates with septicemia: A meta-analysis

J Pediatr. 2001 Jun;138(6):917-20. doi: 10.1067/mpd.2001.114014.

Abstract

A meta-analysis was used to determine whether administering recombinant granulocyte colony-stimulating factor (rG-CSF) to neonates with bacterial septicemia reduces mortality. Five studies were identified, involving 73 rG-CSF recipients and 82 control subjects. Mortality was lower among the rG-CSF recipients (odds ratio, 0.17; CI, 0.03-0.70; P <.05). However, when the non-randomized studies were excluded, the P value was.13. For the subgroups "<2000 g" or "neutropenia," the P value was <.02. Thus the routine use of rG-CSF cannot be recommended for all neonates with sepsis.

Publication types

  • Meta-Analysis
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Humans
  • Infant, Newborn
  • Recombinant Proteins
  • Sepsis / therapy*

Substances

  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor